Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Aug 22;63(4):318-319.
doi: 10.20945/2359-3997000000163.

Pegvisomant for acromegaly: does it always works?

Sebastian J Neggers  1 , Aart J van der Lely  1
Affiliations
Editorial

Pegvisomant for acromegaly: does it always works?

Sebastian J Neggers et al. Arch Endocrinol Metab. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure: SJN and AJvdL have received speakers fees and/or grants from Ipsen, Novartis and Pfizer Inc. They are member of the advisory board of Crinetics.

Comment on

  • Brazilian multicenter study on pegvisomant treatment in acromegaly.
    Boguszewski CL, Huayllas MKP, Vilar L, Naves LA, Ribeiro-Oliveira Junior A, Soares BS, Czepielewski MA, Abucham J, Correa-Silva SR, Bronstein MD, Jallad RS, Duarte FG, Musolino NR, Kasuki L, Gadelha MR. Boguszewski CL, et al. Arch Endocrinol Metab. 2019 Jul 29;63(4):328-336. doi: 10.20945/2359-3997000000159. Arch Endocrinol Metab. 2019. PMID: 31365632 Free PMC article.
  • Pegvisomant in acromegaly: a multicenter real-life study in Argentina.
    Basavilbaso NXG, Ballarino MC, Bruera D, Bruno OD, Chervin AB, Danilowicz K, Fainstein-Day P, Fidalgo SG, Frigeri A, Glerean M, Guelman R, Isaac G, Katz DA, Knoblovits P, Librandi F, Montes ML, Mallea-Gil MS, Manavela M, Mereshian P, Moncet D, Pignatta A, Rogozinsky A, Sago LR, Servidio M, Spezzi M, Stalldecker G, Tkatch J, Vitale NM, Guitelman M. Basavilbaso NXG, et al. Arch Endocrinol Metab. 2019 Aug 22;63(4):320-327. doi: 10.20945/2359-3997000000160. Arch Endocrinol Metab. 2019. PMID: 31460622 Free PMC article.

References

    1. Basavilbaso NXG, Ballarino MC, Bruera D, Bruno OD, Chervin AB, Danilowicz K, et al. Pegvisomant in acromegaly: a multicenter real-life study in Argentina. Arch Endocrinol Metab. 2019;63(4):320-7. - PMC - PubMed
    1. Boguszewski CL, Huayllas MKP, Vilar L, Naves LA, Ribeiro-Oliveira Junior A, Soares BS, et al. Brazilian multicenter study on pegvisomant treatment in acromegaly. Arch Endocrinol Metab. 2019;63(4):328-36. - PMC - PubMed
    1. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342(16):1171-7. - PubMed
    1. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358(9295):1754-9. - PubMed
    1. Buchfelder M, van der Lely AJ, Biller BMK, Webb SM, Brue T, Strasburger CJ, et. Cost-effectiveness of acromegaly treatments: a systematic review. Eur J Endocrinol. 2018;179:419-27. - PubMed

LinkOut - more resources